Ambit's Series D Raises $50M For Kinase Inhibitor Program Nov. 14, 2007 By Trista Morrison With one kinase inhibitor in the clinic and two more in the queue, Ambit Biosciences Corp. raised $49.3 million in a Series D financing round. (BioWorld Today)Read More
RSS